nach oben

Erschienen in:

08.07.2022 | Original Article

Prevalence of FANCM germline variants in BRCA1/2 negative breast and/or ovarian cancer patients from Pakistan

verfasst von: Muhammad Usman Rashid, Noor Muhammad, Umara Shehzad, Faiz Ali Khan, Asif Loya, Ute Hamann

Erschienen in: Familial Cancer | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Abstract

The Fanconi anemia complementation group M (FANCM) gene is a potential candidate for breast/ovarian cancer susceptibility in European populations. Here, we examined the contribution of FANCM germline variants to hereditary breast and/or ovarian cancer in Pakistan. Comprehensive FANCM variant screening was performed in 201 BRCA1 and BRCA2 (BRCA1/2) negative Pakistani patients with and without triple-negative breast cancer (TNBC) and/or ovarian cancer, using denaturing high-performance liquid chromatography analysis (DHPLC) followed by DNA sequencing. Novel variants were tested for their potential effect on protein function using in silico tools. Reverse transcription (RT)-PCR analysis of RNA extracted from one deletion/insertion (delins) variant (p.K1780delinsNGIT) carrier and three non-carriers was performed to evaluate the impact of this variant on splicing. Furthermore, potentially functional variants were evaluated in 200 healthy female controls. A missense variant (p.V1857M) was identified in a 50-year-old TNBC patient with a family history of breast cancer. It was also identified in the index patient´s daughter, who was diagnosed with osteosarcoma at 15 years of age. Further, one delins variant (p.K1780delinsNGIT) was identified in a 45-year-old non-TNBC patient, but not detected in her brother, who was diagnosed with Hodgkin’s lymphoma at 38 years of age. Based on in silico and RNA analyses, p.V1857M and p.K1780delinsNGIT were predicted as variants of uncertain significance (VUS), respectively. Both variants were absent in 200 healthy controls. Our findings suggest a marginal contribution of FANCM variants to hereditary breast/ovarian cancer in Pakistan, which need to be confirmed in larger studies.

Sung H, Ferlay J, Siegel RL (2021) Global cancer statistics 2020 GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J clin 71(3):209–249. https://doi.org/10.3322/caac.21660CrossRef

Mubarik S, Malik SS, Wang Z, Li C, Fawad M, Yu C (2019) Recent insights into breast cancer incidence trends among four Asian countries using age-period-cohort model. Cancer Manag Res 11:8145–8155. https://doi.org/10.2147/CMAR.S208323CrossRef

Mubarik S, Wang F, Fawad M (2020) Trends and projections in breast cancer mortality among four Asian countries (1990–2017): evidence from five stochastic mortality models. Sci Rep 10(1):5480. https://doi.org/10.1038/s41598-020-62393-1CrossRef

Howlett NG, Taniguchi T, Olson S et al (2002) Biallelic inactivation of BRCA2 in Fanconi anemia. Science 297(5581):606–609. https://doi.org/10.1126/science.1073834CrossRef

Levran O, Attwooll C, Henry RT et al (2005) The BRCA1-interacting helicase BRIP1 is deficient in Fanconi anemia. Nat Genet 37(9):931–933. https://doi.org/10.1038/ng1624CrossRef

Xia B, Sheng Q, Nakanishi K et al (2006) Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell 22(6):719–729. https://doi.org/10.1016/j.molcel.2006.05.022CrossRef

Vaz F, Hanenberg H, Schuster B et al (2010) Mutation of the RAD51C gene in a Fanconi anemia-like disorder. Nat Genet 42(5):406–409. https://doi.org/10.1038/ng.570CrossRef

Sawyer SL, Tian L, Kähkönen M et al (2015) Biallelic mutations in BRCA1 cause a new Fanconi anemia subtype. Cancer Discov 5(2):135–142. https://doi.org/10.1158/2159-8290.CD-14-1156CrossRef

Ciccia A, Ling C, Coulthard R et al (2007) Identification of FAAP24, a Fanconi anemia core complex protein that interacts with FANCM. Mol Cell 25(3):331–343. https://doi.org/10.1016/j.molcel.2007.01.003CrossRef

10.

Rahman N, Scott RH (2007) Cancer genes associated with phenotypes in monoallelic and biallelic mutation carriers: new lessons from old players. Hum Mol Genet 16(R1):R60–R66. https://doi.org/10.1093/hmg/ddm026CrossRef

11.

Consortium BCA (2021) Breast cancer risk genes—association analysis in more than 113,000 women. N Engl J Med 384(5):428–439. https://doi.org/10.1056/NEJMoa1913948CrossRef

12.

Kiiski JI, Pelttari LM, Khan S et al (2014) Exome sequencing identifies FANCM as a susceptibility gene for triple-negative breast cancer. Proc Natl Acad Sci USA 111(42):15172–15177. https://doi.org/10.1073/pnas.1407909111CrossRef

13.

Neidhardt G, Hauke J, Ramser J et al (2017) Association Between Loss-of-Function Mutations Within the FANCM Gene and Early-Onset Familial Breast Cancer. JAMA Oncol 3(9):1245–1248. https://doi.org/10.1001/jamaoncol.2016.5592CrossRef

14.

Peterlongo P, Catucci I, Colombo M et al (2015) FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor. Hum Mol Genet 24(18):5345–5355. https://doi.org/10.1093/hmg/ddv251CrossRef

15.

Dicks E, Song H, Ramus SJ et al (2017) Germline whole exome sequencing and large-scale replication identifies FANCM as a likely high grade serous ovarian cancer susceptibility gene. Oncotarget 8(31):50930–50940. https://doi.org/10.18632/oncotarget.15871CrossRef

16.

Stafford JL, Dyson G, Levin NK et al (2017) Reanalysis of BRCA1/2 negative high risk ovarian cancer patients reveals novel germline risk loci and insights into missing heritability. PLoS ONE 12(6):e0178450. https://doi.org/10.1371/journal.pone.0178450CrossRef

17.

Rashid MU, Muhammad N, Khan FA, Hamann U (2015) Absence of the FANCM c.5101C>T mutation in BRCA1/2-negative triple-negative breast cancer patients from Pakistan. Breast Cancer Res Treat 152(1):229–230. https://doi.org/10.1007/s10549-015-3457-5CrossRef

18.

Rashid MU, Zaidi A, Torres D et al (2006) Prevalence of BRCA1 and BRCA2 mutations in Pakistani breast and ovarian cancer patients. Int J Cancer 119(12):2832–2839. https://doi.org/10.1002/ijc.22269CrossRef

19.

Rashid MU, Muhammad N, Naeemi H et al (2019) Spectrum and prevalence of BRCA1/2 germline mutations in Pakistani breast cancer patients: results from a large comprehensive study. Hered cancer clin pract 17:27. https://doi.org/10.1186/s13053-019-0125-5CrossRef

20.

Rashid MU, Muhammad N, Amin A, Loya A, Hamann U (2017) Contribution of BRCA1 large genomic rearrangements to early-onset and familial breast/ovarian cancer in Pakistan. Breast Cancer Res Treat 161(2):191–201. https://doi.org/10.1007/s10549-016-4044-0CrossRef

21.

Rashid MU, Khan FA, Muhammad N, Loya A, Hamann U (2019) Prevalence of PALB2 germline mutations in early-onset and familial breast/ovarian cancer patients from Pakistan. Cancer Res Treat 51(3):992–1000. https://doi.org/10.4143/crt.2018.356CrossRef

22.

Rashid MU, Muhammad N, Faisal S, Amin A, Hamann U (2013) Constitutional CHEK2 mutations are infrequent in early-onset and familial breast/ovarian cancer patients from Pakistan. BMC Cancer 13:312. https://doi.org/10.1186/1471-2407-13-312CrossRef

23.

Rashid MU, Muhammad N, Faisal S, Amin A, Hamann U (2014) Deleterious RAD51C germline mutations rarely predispose to breast and ovarian cancer in Pakistan. Breast Cancer Res Treat 145(3):775–784. https://doi.org/10.1007/s10549-014-2972-0CrossRef

24.

Rashid MU, Gull S, Asghar K, Muhammad N, Amin A, Hamann U (2012) Prevalence of TP53 germ line mutations in young Pakistani breast cancer patients. Fam Cancer 11(2):307–311. https://doi.org/10.1007/s10689-012-9509-7CrossRef

25.

Rashid MU, Muhammad N, Khan FA et al (2020) Prevalence of RECQL germline variants in Pakistani early-onset and familial breast cancer patients. Hered cancer clin pract 18(1):25. https://doi.org/10.1186/s13053-020-00159-6CrossRef

26.

Rashid MU, Muhammad N, Bajwa S et al (2016) High prevalence and predominance of BRCA1 germline mutations in Pakistani triple-negative breast cancer patients. BMC Cancer 16(1):673. https://doi.org/10.1186/s12885-016-2698-yCrossRef

27.

Rashid MU, Muzaffar M, Khan FA et al (2015) Association between the BsmI Polymorphism in the Vitamin D Receptor Gene and breast cancer risk: results from a Pakistani case-control study. PLoS ONE 10(10):e0141562. https://doi.org/10.1371/journal.pone.0141562CrossRef

28.

Richards S, Aziz N, Bale S et al (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology. Gene Med 17(5):405–424. https://doi.org/10.1038/gim.2015.30CrossRef

29.

García MJ, Fernández V, Osorio A et al (2009) Mutational analysis of FANCL, FANCM and the recently identified FANCI suggests that among the 13 known Fanconi Anemia genes, only FANCD1/BRCA2 plays a major role in high-risk breast cancer predisposition. Carcinogenesis 30(11):1898–1902. https://doi.org/10.1093/carcin/bgp218CrossRef

30.

Akbari MR, Malekzadeh R, Lepage P et al (2011) Mutations in Fanconi anemia genes and the risk of esophageal cancer. Hum Genet 129(5):573–582. https://doi.org/10.1007/s00439-011-0951-7CrossRef

31.

Del Valle J, Rofes P (2020) Exploring the role of mutations in fanconi anemia genes in hereditary cancer patients. Cancers. https://doi.org/10.3390/cancers12040829CrossRef

32.

Bonache S, Esteban I, Moles-Fernández A et al (2018) Multigene panel testing beyond BRCA1/2 in breast/ovarian cancer spanish families and clinical actionability of findings. J Cancer Res Clin Oncol 144(12):2495–2513. https://doi.org/10.1007/s00432-018-2763-9CrossRef

33.

Schubert S, van Luttikhuizen JL, Auber B et al (2019) The identification of pathogenic variants in BRCA1/2 negative, high risk, hereditary breast and/or ovarian cancer patients: high frequency of FANCM pathogenic variants. Int J Cancer 144(11):2683–2694. https://doi.org/10.1002/ijc.31992CrossRef

34.

Nguyen-Dumont T, Myszka A, Karpinski P et al (2018) FANCM and RECQL genetic variants and breast cancer susceptibility: relevance to South Poland and West Ukraine. BMC Med Genet 19(1):12. https://doi.org/10.1186/s12881-018-0524-xCrossRef

35.

Nurmi A, Muranen TA, Pelttari LM et al (2019) Recurrent moderate-risk mutations in Finnish breast and ovarian cancer patients. Int J Cancer 145(10):2692–2700. https://doi.org/10.1002/ijc.32309CrossRef

36.

Lhota F, Zemankova P, Kleiblova P et al (2016) Hereditary truncating mutations of DNA repair and other genes in BRCA1/BRCA2/PALB2-negatively tested breast cancer patients. Clin Genet 90(4):324–333. https://doi.org/10.1111/cge.12748CrossRef

37.

Cavaillé M, Uhrhammer N, Privat M et al (2021) Analysis of 11 candidate genes in 849 adult patients with suspected hereditary cancer predisposition. Genes Chromosom Cancer 60(2):73–78. https://doi.org/10.1002/gcc.22911CrossRef

38.

Jarhelle E, Riise Stensland HMF, Hansen GÅM et al (2019) Identifying sequence variants contributing to hereditary breast and ovarian cancer in BRCA1 and BRCA2 negative breast and ovarian cancer patients. Sci Rep 9(1):19986. https://doi.org/10.1038/s41598-019-55515-xCrossRef

39.

Ellingson MS, Hart SN, Kalari KR et al (2015) Exome sequencing reveals frequent deleterious germline variants in cancer susceptibility genes in women with invasive breast cancer undergoing neoadjuvant chemotherapy. Breast Cancer Res Treat 153(2):435–443. https://doi.org/10.1007/s10549-015-3545-6CrossRef

40.

Gracia-Aznarez FJ, Fernandez V, Pita G et al (2013) Whole exome sequencing suggests much of non-BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles. PLoS ONE 8(2):e55681. https://doi.org/10.1371/journal.pone.0055681CrossRef

41.

Figlioli G, Bogliolo M, Catucci I, Caleca L (2019) The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. NPJ Breast Cancer. https://doi.org/10.1038/s41523-019-0127-5CrossRef

42.

Mirabello L, Yu K, Berndt SI et al (2011) A comprehensive candidate gene approach identifies genetic variation associated with osteosarcoma. BMC Cancer 11:209. https://doi.org/10.1186/1471-2407-11-209CrossRef

43.

Zhang MQ (1998) Statistical features of human exons and their flanking regions. Hum Mol Genet 7(5):919–932. https://doi.org/10.1093/hmg/7.5.919CrossRef

44.

Buratti E, Chivers M, Královicová J et al (2007) Aberrant 5’ splice sites in human disease genes: mutation pattern, nucleotide structure and comparison of computational tools that predict their utilization. Nucleic Acids Res 35(13):4250–4263. https://doi.org/10.1093/nar/gkm402CrossRef

45.

Taylor CF, Taylor GR (2004) Current and emerging techniques for diagnostic mutation detection. Mol Diagn Genet Dis. https://doi.org/10.1385/1-59259-432-8:9CrossRef

Titel: Prevalence of FANCM germline variants in BRCA1/2 negative breast and/or ovarian cancer patients from Pakistan
verfasst von: Muhammad Usman Rashid
Noor Muhammad
Umara Shehzad
Faiz Ali Khan
Asif Loya
Ute Hamann
Publikationsdatum: 08.07.2022
Verlag: Springer Netherlands
Erschienen in: Familial Cancer / Ausgabe 1/2023
Print ISSN: 1389-9600
Elektronische ISSN: 1573-7292
DOI: https://doi.org/10.1007/s10689-022-00304-1

Mainstreaming germline genetic testing for patients with pancreatic cancer increases uptake

Original Article

Endoscopic management of familial adenomatous polyposis targeting colorectal lesions greater than 5 mm in size: a single-center retrospective study

Original Article

Preimplantation genetic testing in patients with genetic susceptibility to cancer

Short Communication

A large family with MSH3-related polyposis

Open Access
Short Communication

Truncating TINF2 p.Tyr312Ter variant and inherited breast cancer susceptibility

Open Access
Short Communication

Potential risks associated with the use of ionizing radiation for imaging and treatment of colorectal cancer in Lynch syndrome patients

Open Access
Review

Neu im Fachgebiet Onkologie

Fortgeschrittenes Melanom: Wann den Checkpoint-Inhibitor absetzen?

20.04.2025
Melanom
Nachrichten

Eine ICI-Therapie sollte bei Betroffenen mit fortgeschrittenem Melanom mindestens ein Jahr fortgesetzt werden. Bei anhaltendem Ansprechen kann danach offenbar ohne hohes Risiko ein Therapieabbruch erwogen werden.

Positive Phase IIb-Studie zu mRNA-gestützter CAR-T bei Myasthenia gravis

17.04.2025
AAN-Jahrestagung 2025
Kongressbericht

Eine auf das B-Zell-Reifungsantigen gerichtete mRNA-basierte CAR-T-Zell-Therapie wurde jetzt in einer ersten Phase IIb-Studie zur Behandlung der generalisierten Myasthenia gravis mit Placebo verglichen.

NSCLC: Hirnmetastasen durch elektrische Felder eindämmen

17.04.2025
DGP 2025
Kongressbericht

Zur Behandlung von Hirnmetasen bei nicht-kleinzelligem Lungenkrebs (NSCLC) stehen verschiedene Optionen zur Verfügung. TTFields – eine lokoregionäre, nicht-invasive physikalische Therapie – könnte sich hier einreihen.

Kontrollkoloskopie nach Polypektomie: Wann ist eine zweite Untersuchung nötig?

17.04.2025
Koloskopie
Nachrichten

Wann benötigen polypektomierte Patienten und Patientinnen mehr als eine endoskopische Nachsorgeuntersuchung? Eine Kohortenstudie aus Großbritannien legt eine konkrete Strategie nahe.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Prevalence of FANCM germline variants in BRCA1/2 negative breast and/or ovarian cancer patients from Pakistan

Abstract

Weitere Artikel der Ausgabe 1/2023

Mainstreaming germline genetic testing for patients with pancreatic cancer increases uptake

Endoscopic management of familial adenomatous polyposis targeting colorectal lesions greater than 5 mm in size: a single-center retrospective study

Preimplantation genetic testing in patients with genetic susceptibility to cancer

A large family with MSH3-related polyposis

Truncating TINF2 p.Tyr312Ter variant and inherited breast cancer susceptibility

Potential risks associated with the use of ionizing radiation for imaging and treatment of colorectal cancer in Lynch syndrome patients

Neu im Fachgebiet Onkologie

Fortgeschrittenes Melanom: Wann den Checkpoint-Inhibitor absetzen?

Positive Phase IIb-Studie zu mRNA-gestützter CAR-T bei Myasthenia gravis

NSCLC: Hirnmetastasen durch elektrische Felder eindämmen

Kontrollkoloskopie nach Polypektomie: Wann ist eine zweite Untersuchung nötig?

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten